Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mylan NV (NASDAQ:MYL)

30.72
Delayed Data
As of Aug 18
 +0.16 / +0.52%
Today’s Change
29.39
Today|||52-Week Range
49.42
-19.48%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Generic
MARKET CAP
$16.5B

Company Description

Mylan N.V., is a pharmaceutical company which engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through two segments: Generic and Specialty. The Generic pharmaceutical business is conducted primarily in the U.S. and Canada; Europe; and India, Australia, Japan, New Zealand and Brazil as well as its export activity into emerging markets. The Specialty pharmaceutical business is conducted by Mylan Specialty L.P. The company was founded on July 7, 2014 and is headquartered in Hatfield, United Kingdom.

Contact Information

Mylan NV
Building 4
Hatfield Hertfordshire EN6 1AG
P:441707853000
Investor Relations:

Employees

Shareholders

Individual stakeholders5.53%
Mutual fund holders38.65%
Other institutional36.13%

Top Executives

Heather M. BreschChief Executive Officer & Executive Director
Rajiv MalikPresident & Executive Director
Kenneth Scott ParksChief Financial Officer
Adele M. GulfoChief Strategy Officer
Anthony MauroChief Commercial Officer